News

Investor's Business Daily on MSN7mon
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
One of the key players, Avidity Biosciences, is feeling particularly bullish about its chances. Last month, Fulcrum ...
Hosted on MSN11mon
Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock
S AN DIEGO, June 13, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody ...
Yahoo Finance2mon
Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock?
Avidity Biosciences, Inc. (RNA) shares soared 11.3% in the last trading session to close at $29.77. The move was backed by solid volume with far more shares changing hands than in a normal session.
Seeking Alpha8mon
Avidity Biosciences: Good Prospects, But We Are A Little Late
Avidity Biosciences excels in antibody oligonucleotide conjugates, with its stock tripling in the past year due to innovative clinical advancements. Lead asset AOC1001 shows promising results in ...
Morningstar3mon
Avidity Biosciences Honors Rare Disease Day® and Global Efforts to Support People and Families Impacted by Rare Neuromuscular Diseases
SAN DIEGO, Feb. 28, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody ...
Seeking Alpha1y
Avidity Biosciences: Targeting A First Ever Approval In DM1 With Improving Data
Avidity Biosciences stock has gained more than 20% in the past five days due to positive long-term data for its lead candidate, AOC 1001, in the MARINA-OLE trial in DM1 patients. The company's ...
Nasdaq10mon
Avidity Biosciences Announces Appointment of John B. Moriarty, Jr. as Chief Legal Officer
SAN DIEGO, Aug. 5, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide ...
KTLA1mon
Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
SAN DIEGO, April 8, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody ...
Nasdaq9mon
Avidity Biosciences Announces Proposed Public Offering of Common Stock
SAN DIEGO, Aug. 13, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody ...